![Robert O’Holla](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert O’Holla
President chez
R.O.H. Consulting LLC
Profil
Robert O’Holla currently works at Gynesonics, Inc., as Director, Nuvaira, Inc., as Director, CeQur SA, as Director & Executive VP-Regulatory Affairs from 2012, Endeavour Vision SA, as Operating Partner from 2014, and R.O.H.
Consulting LLC, as President from 2008.
Mr. O’Holla also formerly worked at Regulatory Affairs Professionals Society, as Chairman, InSite Vision, Inc., as Independent Director from 2011 to 2015, Biosurface Engineering Technologies, Inc., as Director, Johnson & Johnson, as Vice President-Regulatory Affairs from 1990 to 2008, and PTV Sciences LP, as Senior Advisor.
Mr. O’Holla received his Masters Business Admin degree from Fairleigh Dickinson University, undergraduate degree from Union College (New York), and undergraduate degree from Upsala College.
Postes actifs de Robert O’Holla
| Sociétés | Poste | Début |
|---|---|---|
CeQur SA
 CeQur SA Medical SpecialtiesHealth Technology Develops medical devices for diabetes patients | Directeur/Membre du Conseil | - |
R.O.H. Consulting LLC | President | 09/06/2011 |
Gynesonics, Inc.
 Gynesonics, Inc. Medical SpecialtiesHealth Technology Develops medical devices for diagnostic intrauterine imaging and trans cervical treatment of symptomatic uterine fibroids | Directeur/Membre du Conseil | - |
Endeavour Vision SA
 Endeavour Vision SA Investment ManagersFinance EV develops a long-term investment strategy with their entrepreneurs. Their investment objective is to grow firms and to create a market leader in a new field. They focus on developing businesses active in industries including information technology, biotech, medtech and cleantech. They concentrate on various stages such as early to expansion-stage as well as spin-offs and restarts. Their geographic focus is pan-European. Specifically, their technology-sector investments are concentrated in Norway, Sweden, Finland, UK, Ireland, Germany, Switzerland, France, Italy and Portugal. Beyond these countries, they also consider taking a co-lead or a syndicate role. For their life sciences investments, they primarily target Switzerland, France and Germany. Four key investment criteria they consider before investment are hyper-growth market potential, world-class technology, capital efficiency and ambitious management team. EV's preferred role is to be lead investor or possibly co-lead. They also consider being syndicate partner on some occasions. EV's investment horizon is generally 10 years, with that timeframe extended for firms in hyper-growth stage. On average, their investments typically take five years to mature. The majority of their exits are through a listing in one of the main markets while many of the VC-backed firms are acquired. | Private Equity Investor | 01/01/2014 |
Nuvaira, Inc.
 Nuvaira, Inc. Medical SpecialtiesHealth Technology Develops medical devices for treating lung diseases | Directeur/Membre du Conseil | - |
Anciens postes connus de Robert O’Holla
| Sociétés | Poste | Fin |
|---|---|---|
| INSITE VISION INC. | Directeur/Membre du Conseil | 02/11/2015 |
| JOHNSON & JOHNSON | Conseiller Juridique Général | 01/05/2008 |
Biosurface Engineering Technologies, Inc.
 Biosurface Engineering Technologies, Inc. Medical SpecialtiesHealth Technology Engages in the development of proprietary therapeutic peptides as medical devices to improve bone and soft tissue repair | Directeur/Membre du Conseil | - |
Regulatory Affairs Professionals Society
 Regulatory Affairs Professionals Society Miscellaneous Commercial ServicesCommercial Services Operates as NPO that offers healthcare products | Président | - |
| ░░░ ░░░░░░░░ ░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░░░░░░░░░░░░ | - |
Formation de Robert O’Holla
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
85
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
InSite Vision, Inc.
 InSite Vision, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets ophthalmic pharmaceutical products | Health Technology |
Johnson & Johnson
 Johnson & Johnson Pharmaceuticals: MajorHealth Technology Operates as an investment holding company with interests in health care products | Health Technology |
Biosurface Engineering Technologies, Inc.
Biosurface Engineering Technologies, Inc. Medical SpecialtiesHealth Technology Engages in the development of proprietary therapeutic peptides as medical devices to improve bone and soft tissue repair | Health Technology |
Gynesonics, Inc.
Gynesonics, Inc. Medical SpecialtiesHealth Technology Develops medical devices for diagnostic intrauterine imaging and trans cervical treatment of symptomatic uterine fibroids | Health Technology |
Regulatory Affairs Professionals Society
Regulatory Affairs Professionals Society Miscellaneous Commercial ServicesCommercial Services Operates as NPO that offers healthcare products | Commercial Services |
Nuvaira, Inc.
Nuvaira, Inc. Medical SpecialtiesHealth Technology Develops medical devices for treating lung diseases | Health Technology |
Fairleigh Dickinson University
 Fairleigh Dickinson University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Union College (New York)
 Union College (New York) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PTV Sciences LP
 PTV Sciences LP Investment ManagersFinance PTV Healthcare Capital seeks invests in companies located in the United States. The firm focuses on companies operating in the fields of medical devices, healthcare services, and healthcare technology sectors. It provides financing for early and later stage capital requirements. | Finance |
Endeavour Vision SA
Endeavour Vision SA Investment ManagersFinance EV develops a long-term investment strategy with their entrepreneurs. Their investment objective is to grow firms and to create a market leader in a new field. They focus on developing businesses active in industries including information technology, biotech, medtech and cleantech. They concentrate on various stages such as early to expansion-stage as well as spin-offs and restarts. Their geographic focus is pan-European. Specifically, their technology-sector investments are concentrated in Norway, Sweden, Finland, UK, Ireland, Germany, Switzerland, France, Italy and Portugal. Beyond these countries, they also consider taking a co-lead or a syndicate role. For their life sciences investments, they primarily target Switzerland, France and Germany. Four key investment criteria they consider before investment are hyper-growth market potential, world-class technology, capital efficiency and ambitious management team. EV's preferred role is to be lead investor or possibly co-lead. They also consider being syndicate partner on some occasions. EV's investment horizon is generally 10 years, with that timeframe extended for firms in hyper-growth stage. On average, their investments typically take five years to mature. The majority of their exits are through a listing in one of the main markets while many of the VC-backed firms are acquired. | Finance |
Upsala College
 Upsala College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CeQur SA
CeQur SA Medical SpecialtiesHealth Technology Develops medical devices for diabetes patients | Health Technology |
R.O.H. Consulting LLC |
